Woman of the Week: iSpecimen's Jill Mullan

Need biospecimens? iSpecimen aims to be the Amazon of research materials, and Jill Mullan is changing the game.

By Taren Grom • April 13, 2022

Biotech goes Hollywood

A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.

By Taren Grom • April 13, 2022

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

'Bootcamp' helps rare disease advocates learn the ropes of drug development

Ultragenyx’s CEO on why supporting others in rare diseases pays dividends all around.

By Kim Ribbink • April 12, 2022

Optinose CEO senses big opportunities for the company's nasal delivery device

Peter Miller explains how a repackaged sinus drug has won late-stage clinical success.

By Jared Whitlock • April 11, 2022

Woman of the Week: Lyell Immunopharma's Liz Homans

The CEO has the company poised to capitalize on its moment to address T cell exhaustion.

By Taren Grom • April 6, 2022

Seeing yourself at the top: Alnylam CEO on why representation matters

Dr. Yvonne Greenstreet became just the sixth woman in the world to head up a biopharma company with a market cap of more than $5 billion when she took on the role of CEO in January.

By Alexandra Pecci • April 6, 2022

An analyst turned pharma CEO learns the art of operations

Under Apurva Saraf’s guidance, Cosette Pharmaceuticals is pivoting wholeheartedly into the cardio space.

By Jared Whitlock • April 5, 2022

Clinical trial recruitment hits the local pharmacy counter

CVS Health's partnership with clinical trial software company Medable is designed to make recruitment easier for patients and drug makers alike.

By Kelly Bilodeau • April 5, 2022

Time-saving tech lights Alcon's path into digital innovation

Kevin Yapp, global head or omni-channel transformation at the Swiss eye health company shares why the customer should be a  North Star when developing digital tools.

By Kim Ribbink • April 4, 2022

Sangamo has its finger on the next evolution of gene editing

Sangamo Therapeutics' CEO Sandy Macrae is bullish on his company’s ability to transform the genomic medicine arena.

By Taren Grom • March 31, 2022

Woman of the Week: Daré Bioscience's Sabrina Martucci Johnson

The CEO is setting a path to transform women’s health at an opportune time.

By Taren Grom • March 30, 2022

Another pandemic threat looms, and the antibacterial drug pipeline still isn't keeping up

A recent report from BIO details challenges in the antibiotic market — and new policy measures that could help.

By Kelly Bilodeau • March 23, 2022

Why Astellas is adopting a 'focus area approach' to partnerships

Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.

By Kim Ribbink • March 22, 2022

Psychedelics without the party: Inside MindMed's LSD makeover

MindMed’s CEO, Robert Barrow, on the company’s latest moves to ‘change the world’ with psychedelics.

By Alexandra Pecci • March 21, 2022

BioMarin’s new global head of advocacy is tackling the holy grail of patient engagement

In her new role, Dr. Roz is keeping her patient-first approach.

By Taren Grom • March 21, 2022

Attralus' medical officer believes systemic amyloidosis could be 'solvable'

Gregory Bell is not just aiming to treat amyloidosis, but eventually cure it.

By Robin Robinson • March 18, 2022

COVID-19 trials aren't the only studies that can achieve super speed

Is it possible to enroll clinical trials 10 times faster than the industry’s average speed? Elligo Health Research thinks so.

By Kelly Bilodeau • March 15, 2022

Medigene's CEO on striking a collaboration deal with BioNTech

The two companies recently announced a $29 million collaboration. 

By Jared Whitlock • March 15, 2022

Clearing hurdles in rare cancer drug development

Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.

By Kim Ribbink • March 14, 2022

Liquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage

The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.

By Taren Grom • March 14, 2022

Biote CEO: Employers need to normalize women's health issues in the workforce

A survey by Biote reveals the impact of menopause on working women.

By Robin Robinson • March 14, 2022

Ultragenyx's CEO on building a 'next-gen' rare disease company

How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.

By Kim Ribbink • March 9, 2022

From angel to operator: The unlikely journey of Endevica Bio's CEO

Russell Potterfield is honing his new found passion for the space to guide Endevica into the clinic.

By Jared Whitlock • March 9, 2022

Woman of the Week: Genentech's Quita Highsmith

Quita Highsmith is changing how Genentech approaches diversity and inclusion across the board — from drug development to career advancement.

By Taren Grom • March 9, 2022

Horizon’s VP of R&D on her ascent in biotech — and bringing other female scientists along for the ride

Elizabeth Thompson is guiding Horizon through new drug approvals while leading the way for young women in STEM.

By Alexandra Pecci • March 8, 2022